Maricel Apuli, Chief Accounting Officer at BridgeBio Pharma, Inc. (BBIO), sold 2,000 shares at $71.58 ($143K) on 2026-04-30, disclosed to the SEC on 2026-05-04.
Scheduled sale ($143k) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBIO | SELL | 2026-02-18 | $38K | — | Filing → |
| BBIO | SELL | 2025-12-10 | $149K | — | Filing → |
| BBIO | SELL | 2025-08-11 | $45K | — | Filing → |